Chicago Tribune (Columbia News Service): New drug to fight cancer may get the cold shoulder, 2007-Feb-27, by Denise Heckbert
A new treatment for cancer could cost as little as $2 a dose and be as easy to administer as taking a pill or getting a shot. But scientists fear that their struggles to find financing for further research could keep the treatment from ever reaching the public.
In January, scientists working at the University of Alberta discovered that dichloroacetate, or DCA, a drug long used to treat rare metabolic diseases, seemed to halt the spread of cancer.
The discovery has been met with cautious optimism by the medical community and with excitement among cancer patients eager to participate in clinical trials. However, because the drug is not patented and can be produced by multiple companies, it is unlikely to be profitable and therefore has yet to appeal to the pharmaceutical companies that researchers typically rely on to finance clinical trials.
"There is no real way a company could invest and get a return on this," said Dr. Evangelos Michelakis, whose team of scientists conducted the research.
Link: Official University of Alberta DCA Site.
In order to be absolutely certain that DCA is effective and safe in patients with cancer, studies involving thousands of patients with different cancers, from different hospitals and different countries have to be conducted. Often, direct comparisons of one experimental treatment with other standard therapies are required. These large-scale trials will take years to complete and will require hundreds of millions of dollars.
However, smaller and more focused trials can occur much faster. The funding required for such trials is less (in the range of hundreds of thousands of dollars) and the procedures are easier than in drugs that have never before tried in any human being. Still, protocols of such trials need to be approved by local and federal agencies and funding secured
A number of physicians and scientists from the University of Alberta and the Alberta Cancer Board have already started working together and have received commitment from the leadership of these institutions to help make these trials happen as soon as possible. We hope that initiation of trials will occur shortly, i.e. within a few months. We plan to post our progress towards this goal on this website.
How can I help?
We appreciate your interest, and support and we have been touched by your kind words. We also understand the agony in many of you that you see your loved ones in desperate need of a treatment or a hope. We have been working on this for at least 2 years now and we will continue to work hard in order to determine whether this drug can actually benefit human beings with cancer. Your continued support of research in general is greatly appreciated by all of us in this field and it is important since a great deal of funding comes directly from the people (tax payer money coming to us through federal funding agencies like CIHR or charities). If you want to directly support this effort (that at this time receives no financial support from “for profit” organizations, pharmaceutical or private companies), you can do so in this web site.